title: Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis.
abstract: BACKGROUND
  Psoriasis is associated with a systemic inflammation and an increased frequency of the metabolic syndrome, both of which are believed to link psoriasis to an increased risk of cardiovascular disease.
  
  
  OBJECTIVE
  The study aimed to investigate the systemic expression of markers of cardiovascular risk and determine their response to ultraviolet B therapy and treatment with the tumor necrosis factor-alfa inhibitor, etanercept.
  
  
  METHODS
  Six markers of cardiovascular risk were measured in 28 patients with psoriasis and 28 control subjects.
  
  
  RESULTS
  Five of the 6 investigated markers were elevated in patients with psoriasis. Four of these correlated to the body mass index and waist-hip ratio, suggesting a link to the metabolic syndrome. Total plasminogen activator inhibitor-1 remained elevated independently of these factors. The levels of the investigated risk markers decreased considerably after tumor necrosis factor-alfa inhibitor treatment but remained unaffected by ultraviolet therapy.
  
  
  CONCLUSIONS
  A relatively limited study population and nonrandomization are limitations.
  
  
  CONCLUSIONS
  These findings suggest that the choice of treatment in psoriasis may influence the cardiovascular risk in patients with psoriasis and the metabolic syndrome.
authors.affiliation: Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
authors.forename: Gunnthorunn
authors.initials: G
authors.lastname: Sigurdardottir
authors.affiliation: Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
authors.forename: Anna-Karin
authors.initials: AK
authors.lastname: Ekman
authors.affiliation: Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Mona
authors.initials: M
authors.lastname: Ståhle
authors.affiliation: Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Bivik
authors.affiliation: Ingrid Asp Psoriasis Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. Electronic address: charlotta.enerback@liu.se.
authors.forename: Charlotta
authors.initials: C
authors.lastname: Enerbäck
mesh_terms: D000328:Adult; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D019040:E-Selectin / Q000097:blood; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008297:Male; D020782:Matrix Metalloproteinases / Q000097:blood; D008875:Middle Aged; D009195:Peroxidase / Q000097:blood; D011565:Psoriasis / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000009:adverse effects / Q000379:methods*
chemical_list: D019040:E-Selectin; D007074:Immunoglobulin G; D018836:Inflammation Mediators; D018124:Receptors, Tumor Necrosis Factor; D018799:Intercellular Adhesion Molecule-1; D009195:Peroxidase; D020782:Matrix Metalloproteinases; D000068800:Etanercept
keywords: cardiovascular risk; matrix metalloproteinase-9; myeloperoxidase; psoriasis; soluble E-selectin; soluble intercellular adhesion molecule-1; soluble vascular cell adhesion molecule-1; total plasminogen activator inhibitor-1; tumor necrosis factor-alfa inhibitor; ultraviolet B